Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Dissolving or eluting from solid or gel matrix
Reexamination Certificate
2001-02-20
2003-05-13
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Dissolving or eluting from solid or gel matrix
C424S001110, C600S003000, C600S004000
Reexamination Certificate
active
06562317
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is directed to novel compositions for delivery in vivo and preferably to vascular sites. Such compositions are particularly suited for treating solid mass tumors via catheter delivery of the composition to a vascular site leading to or in the solid mass tumor and subsequent embolization of this vascular site.
In particular, the compositions of this invention comprise a biocompatible polymer, a biocompatible solvent and a radioactive agent which provides therapeutic doses of radiation.
REFERENCES
The following publications are cited in this application as superscript numbers:
1
Mandai, et al., “Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer”,
J. Neurosurg.,
77:497-500 (1992)
2
Kinugasa, et al., “Direct Thrombois of Aneurysms with Cellulose Acetate Polymer”,
J. Neurosurg.,
77:501-507 (1992)
3
Casarett and Doull's
Toxicology,
Amdur, et al., Editors, Pergamon Press, New York, pp. 661-664 (1975)
4
Greff, et al., U.S. Pat. No. 5,667,767, for “Novel Compositions for Use in Embolizing Blood Vessels”, issued Sep. 16, 1997
5
Greff, et al., U.S. Pat. No. 5,580,568 for “Cellulose Diacetate Compositions for Use in Embolizing Blood Vessels”, issued Dec. 3, 1996
6
Kinugasa, et al., “Early Treatment of Subarachnoid Hemorrhage After Preventing Rerupture of an Aneurysm”,
J. Neurosurg.,
83:34-
41
(1995)
7
Kinugasa, et al., “Prophylactic Thrombosis to Prevent New Bleeding and to Delay Aneurysm Surgery”,
Neurosurg.,
36:661 (1995)
8
Taki, et al., “Selection and Combination of Various Endovascular Techniques in the Treatment of Giant Aneurysms”,
J. Neurosurg.,
77:37-24 (1992)
9
Evans, et al., U.S. patent application Ser. No. 08/802,252 for “Novel Compositions for Use in Embolizing Blood Vessels”, filed Feb. 19, 1997
10
Castaneda-Zuniga, et al.,
Interventional Radiology,
in Vascular Embolotherapy, Part 1, 1:9-32, Williams & Wilkins, Publishers (1992)
11
Rabinowitz, et al., U.S. Pat. No. 3,527,224 for “Method of Surgically Bonding Tissue Together”, issued Sep. 8, 1970
12
Hawkins, et al., U.S. Pat. No. 3,591,676 for “Surgical Adhesive Compositions”, issued Jul. 6, 1971
13
Encyclopedia of Medical Devices and Instrumentation, J. G. Webster, Editor (1988) 4:2456
14
Tanabe, U.S. Pat. No. 5,443,454 for “Catheter for Embolectomy”, issued Aug. 22, 1995
15
Sitton, “
Early and Late Radiation
-
Induced Skin Alterations Part I:Mechanisms of Skin Changes”, Oncology Nursing Forum,
19(5): 801-807 (1992)
16
Dunn, et al., U.S. Pat. No. 4,938,763 for “Biodegradable In-Situ Forming Implants and Methods of Producing Same”, issued Jul. 3, 1990
17
Hellman, “
CANCER, Principles
&
Practice of Oncology”,
4th Ed., Volume 1, Chapter 15,
“Principles of Radiation Therapy
”, pp. 248-250 (1993)
18
“CANCER, Principles
&
Practice of Oncology”,
4th Ed., Volume 1,
“Cancer Treatment
”, pp. 545-548 (1993)
All of the above publications are herein incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated herein by reference in its entirety.
2. State of the Art
Current therapeutic regimens for treating solid mass tumors in mammals include radiation therapy, vascular embolization, chemotherapy with cytotoxic agents, open surgery, and the like as well as combinations of two or more of the above.
Radiation therapy includes both the external and internal exposure of the tumor to ionizing radiation to induce tumor necrosis. In a first instance, application of external sources of radiation, known as teletherapy, has been used to treat solid mass tumors. Such external radiation sources include X-rays from a linear accelerator, gamma-rays generated from isotopes such as cobalt-60 (administered with a telecobalt apparatus) and electron beams generated from specialized radiotherapy machines or high energy linear accelerators. The use of external sources of radiation requires careful preplanning so that the patient is placed in the exact position necessary to treat the solid mass tumor. The precise positioning of the patient and application of radiation is important so as to minimize irradiation and tissue damage to unintended areas of the body. Nevertheless, external irradiation of the tumor induces skin damage to the exposed skin
15
and is not amenable to deep tumors because the external radiation gives unwanted tissue absorption around the tumor area.
Another technique, brachytherapy, is internal radiotherapy on solid mass tumors in a mammal by the in vivo placement of radioactive sources close to or in the tumor where destruction of non-cancerous tissue is limited.
17
Specifically, the dose distribution of the radiation is determined by the inverse square law and, accordingly, radiation effects on tissues at any distance from the radioactive source is limited. Examples of brachytherapy are interstitial or intracavitary radiation used in the treatment of many urologic, lung, gynecological and oral tumors. In one example of this technique, a removable applicator is used to direct radiation to desired areas while limiting exposure to other tissues. Nevertheless, brachytherapy is not amenable to tumors inaccessible by conventional surgical techniques.
Still another technique for the treatment of solid mass tumors is vascular embolization of blood vessels feeding the tumor to induce necrosis of the tumor tissue by obstructing its arterial supply. One preferred example of this technique is direct embolization of blood vessels by, e.g., catheter techniques which permit the selective placement of the catheter at the vascular site to be embolized which can be as small as 1 mm in diameter.
Preferred embolic compositions for catheter delivery to the vascular site include a biocompatible solvent, a biocompatible polymer and a contrast agent.
1-8, 14
The biocompatible solvent is miscible or soluble in blood or other body fluid and also solubilizes the biocompatible polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood or other body fluid. The contrast agent is selected to permit the physician to fluoroscopically visualize delivery of this composition. Upon contact with the blood or other body fluids, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates in the presence of the water insoluble contrast agent and embolizes the blood vessel.
The use of vascular embolization, by itself, in the treatment of solid mass tumors is complicated by the fact that, upon embolization of the blood vessel feeding the tumor, alternative vascular routes can be generated by the tumor which continue to feed the tumor.
Another example of embolization techniques in the treatment of solid mass tumors is termed “chemoembolization” which combines the use of intra-arterial high-dose chemotherapy with obstruction of the tumor vascular bed to provide a two-prong attack on the tumor.
17
The chemotherapeutic agent leaches from the deposited embolic agent to provide prolonged exposure time of the tumor to the chemotherapeutic agent and the embolic agent adds an ischemic component to enhance tumor necrosis. One example of this technique includes the placement of particulate carriers with chemotherapeutic agents bound to microspheres or contained in microcapsules (e.g., liposomes) at the vascular site.
However, the chemotherapeutic agent is susceptible to migration and systemic delivery in vivo with potential side effects in the patient.
In view of the above, there exists a continuing need to improve the treatment regimens for therapeutically treating solid mass tumors and, in particular, in vivo treatment of such tumors.
SUMMARY OF THE INVENTION
This invention is directed to novel embolic compositions comprising a radioactive agent which are delivered e.g., to the vascular site, as a fluid and which solidify in vivo to form a solid, coherent mass. In a preferred embodiment, these compositions are employed in novel methods to emb
Greff Richard J.
Wallace George
Burns Doane Swecker & Mathis L.L.P.
Hartley Michael G.
Micro Therapeutics Inc.
LandOfFree
Radioactive embolizing compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radioactive embolizing compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioactive embolizing compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030723